A study by the National Network Genomic Medicine (NNGM) Lung Cancer Collaborator Group found that patients (PD-L1 ≥50%) carrying KRAS mutations, especially G12C and TP53 co-mutations, have better survival after receiving treatment with pembrolizumab (51–53). The gene discussed is KRAS; the disease is lung carcinoma.